ABBV vs NVDA: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and NVIDIA Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
AbbVie Inc. · Healthcare
$261.07
+1.2% upside to fair value
Grade C
High Quality
VS
NVIDIA Corporation · Technology
$210.69
+45.0% upside to fair value
Grade B
High Quality
QuantHub Verdict
NVDA has more upside to fair value
(+45.0%).
NVDA trades at a lower forward P/E
(32.1x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
NVDA |
| Current Price |
$261.07 |
$210.69 |
| Fair Value Estimate |
$264.30 |
$305.50 |
| Upside to Fair Value |
+1.2%
|
+45.0%
|
| Market Cap |
$461.3B |
$5,103.1B |
| Forward P/E |
128.0x
|
32.1x
|
| EV / EBITDA |
31.0x
|
26.5x
|
| Price / Sales |
7.3x
|
20.1x
|
| Price / FCF |
22.1x
|
42.9x
|
| Revenue Growth YoY |
+12.4%
|
+85.2%
|
| Gross Margin |
70.7%
|
74.1%
|
| Operating Margin |
27.6%
|
64.0%
|
| Return on Equity |
68.0%
|
111.7%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
4.52%
|
2.33%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology and aesthetics. The company is transitioning from its historical Humira dominance, which has faced loss of exclusivity, toward high-growth assets like Skyrizi and Rinvoq that are driving robust revenue growth of 12.4% in the most recent quarter. Despite strong revenue growth and a dura…
NVIDIA Corporation is a leading technology company specializing in semiconductors, particularly GPUs and AI accelerators, with a dominant market position in AI training markets holding over 80% share. The company exhibits exceptional business quality with a founder-led management team boasting over 30 years of continuous leadership, very high profitability with gross margins above 74% and net mar…
Accumulation Zones
| Metric |
ABBV |
NVDA |
| Zone Low |
$198.23 |
$229.12 |
| Zone High |
$224.66 |
$259.68 |
| In Buy Zone? |
No
|
Yes
|